Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20393747rdf:typepubmed:Citationlld:pubmed
pubmed-article:20393747lifeskim:mentionsumls-concept:C0278701lld:lifeskim
pubmed-article:20393747lifeskim:mentionsumls-concept:C0007589lld:lifeskim
pubmed-article:20393747lifeskim:mentionsumls-concept:C0205615lld:lifeskim
pubmed-article:20393747lifeskim:mentionsumls-concept:C0026019lld:lifeskim
pubmed-article:20393747lifeskim:mentionsumls-concept:C1441616lld:lifeskim
pubmed-article:20393747lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:20393747lifeskim:mentionsumls-concept:C0868928lld:lifeskim
pubmed-article:20393747pubmed:issue5lld:pubmed
pubmed-article:20393747pubmed:dateCreated2010-5-7lld:pubmed
pubmed-article:20393747pubmed:abstractTextPathologic and prognostic data of nine patients with mitochondrion-rich carcinomas (MRC) were compared retrospectively to data of 101 patients with conventional gastric adenocarcinomas. MRC was defined as a tumour composed predominantly, or entirely, of columnar adenocarcinoma cells with eosinophilic cytoplasm and a strong supranuclear immunoreactivity for antimitochondrial antibody. Electron microscopy confirmed supranuclear distribution of mitochondria in MRC while immunostaining pattern was irregular or absent in the remaining 101 cases. MRC exhibited a tubulopapillary or cribriform growth pattern with focal infiltration of neutrophils in the tumour stroma. Prominent necrosis was present including segmental and intraluminal "dirty necrosis", while mitotic and ki-67 proliferative rates were low. MRC showed immunohistochemical findings compatible with gastric differentiation (CK7+/CK20-/CDX-) When MRC were compared with non-MRC carcinomas, tumour size (< 4 cm vs >4 cm, P < 0.01) , frequency of lymph node metastases (11% vs. 80%, P < 0.01), low stage (I, II) at diagnosis (100% vs. 56%, P < 0.01), Goseki's group I (100% vs. 6%, P < 0.01), and better survival (0% vs. 70%, P < 0.01) differed significantly. Our results suggest that MRC of the stomach may be considered a low-grade malignancy with an excellent prognosis.lld:pubmed
pubmed-article:20393747pubmed:languageenglld:pubmed
pubmed-article:20393747pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20393747pubmed:citationSubsetIMlld:pubmed
pubmed-article:20393747pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20393747pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20393747pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20393747pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20393747pubmed:statusMEDLINElld:pubmed
pubmed-article:20393747pubmed:monthMaylld:pubmed
pubmed-article:20393747pubmed:issn1432-2307lld:pubmed
pubmed-article:20393747pubmed:authorpubmed-author:FedeleFrances...lld:pubmed
pubmed-article:20393747pubmed:authorpubmed-author:ParisiAntonin...lld:pubmed
pubmed-article:20393747pubmed:authorpubmed-author:CarusoRosario...lld:pubmed
pubmed-article:20393747pubmed:authorpubmed-author:NapoliPatrizi...lld:pubmed
pubmed-article:20393747pubmed:authorpubmed-author:ZuccalàValeri...lld:pubmed
pubmed-article:20393747pubmed:authorpubmed-author:NaniaAlbertoAlld:pubmed
pubmed-article:20393747pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20393747pubmed:volume456lld:pubmed
pubmed-article:20393747pubmed:ownerNLMlld:pubmed
pubmed-article:20393747pubmed:authorsCompleteYlld:pubmed
pubmed-article:20393747pubmed:pagination499-505lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:meshHeadingpubmed-meshheading:20393747...lld:pubmed
pubmed-article:20393747pubmed:year2010lld:pubmed
pubmed-article:20393747pubmed:articleTitleMitochondrion-rich differentiated adenocarcinomas of the stomach: clinicopathological, immunohistochemical and electron microscopy study of nine cases.lld:pubmed
pubmed-article:20393747pubmed:affiliationDipartimento di Patologia Umana, Policlinico Universitario, Messina, Italy. rosariocaruso@tin.itlld:pubmed
pubmed-article:20393747pubmed:publicationTypeJournal Articlelld:pubmed